Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871254 | 0.91 | TSHR (0.71) | TSHRRAB9ASMN1; SMN2NPC1AVPR2 | |
| SCHEMBL4868028 | 0.89 | TSHR (0.61) | TSHRRAB9ASMN1; SMN2NPC1AVPR2 | |
| SCHEMBL4871829 | 0.87 | TSHR (0.54) | TSHRRAB9ASMN1; SMN2NPC1AVPR2 | |
| SCHEMBL4871766 | 0.87 | TSHR (0.68) | TSHRRAB9ASMN1; SMN2NPC1AVPR2 | |
| SCHEMBL4871897 | 0.86 | MAPT (0.63) | TSHRRAB9ASMN1; SMN2NPC1AVPR2 | |
| SCHEMBL4868650 | 0.85 | TSHR (0.66) | TSHRRAB9ASMN1; SMN2NPC1AVPR2 | |
| SCHEMBL4871280 | 0.84 | TSHR (0.92) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4863867 | 0.82 | TSHR (0.95) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4870617 | 0.82 | TSHR (0.95) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4869603 | 0.82 | TSHR (0.95) | TSHRRAB9ASMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | TSHR 261/4885RAB9A 4025/4885SMN1; SMN2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.